Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site Pathway, in Adults with Diabetic Macular Edema at AAO 2026
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa
Merck Enters into Exclusive Global License Agreement with SciBrunch Therapeutics for SPR2015, an Investigational Oral KRAS G12D Inhibitor
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
U.S. FDA Approves WELIREG® Plus LENVIMA® for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component
Merck's Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
U.S. FDA Approves Update to the Label for WINREVAIR to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension
Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
Merck's KEYTRUDA QLEX Approved in Japan for Subcutaneous Administration for All KEYTRUDA® Indications Approved in Japan
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® Plus Padcev® as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer
SAGA Metals Reports Final Titanium, Vanadium and Iron Assays from MRE Drilling--Maiden Mineral Resource Estimate Imminent
